Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H66O14 |
Molecular Weight | 794.965 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4)O[C@@H]3C)O[C@@H]2C)O[C@@H]1C
InChI
InChIKey=IYJMSDVSVHDVGT-PEQKVOOWSA-N
InChI=1S/C42H66O14/c1-20-37(49-6)29(43)16-35(51-20)55-39-22(3)53-36(18-31(39)45)56-38-21(2)52-34(17-30(38)44)54-25-9-11-40(4)24(14-25)7-8-27-28(40)15-32(46)41(5)26(10-12-42(27,41)48)23-13-33(47)50-19-23/h13,20-22,24-32,34-39,43-46,48H,7-12,14-19H2,1-6H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,34+,35+,36+,37-,38-,39-,40+,41+,42+/m1/s1
Molecular Formula | C42H66O14 |
Molecular Weight | 794.965 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 21 / 21 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/2693372
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2693372
Beta-methyl digoxin (beta-methyl digoxin; Metildigoxin (INN, or medigoxin BAN, or methyldigoxin) is a methyl derivative (methyl group in position 4 of the digitoxose residue) of digoxin is a cardiac glycoside, a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia (irregular heartbeat). The substance is closely related to digoxin; it differs from the latter only by an O-methyl group on the terminal monosaccharide.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
The effects of digoxin and beta-methyldigoxin on the heart rate of decompensated patients with atrial fibrillation. | 1977 Feb |
|
[Serum digoxin in children treated with beta methyl digoxin]. | 1991 Nov-Dec |
|
[Acute psychoses caused by digitalis poisoning]. | 1991 Nov-Dec |
|
P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. | 2001 Mar |
|
[Application of HPLC/MS for evaluation of fatal poisoning with digoxin in the aspect of medico-legal evidence]. | 2003 Jan-Mar |
|
Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats. | 2005 Jun |
|
Selective inhibition of brain Na,K-ATPase by drugs. | 2006 |
|
[Isolated non-compaction of the left ventricular myocardium in a neonate--a case report]. | 2006 Dec |
|
Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. | 2007 Jan-Feb |
|
Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system. | 2009 Aug 7 |
|
Free and total digoxin in serum during treatment of acute digoxin poisoning with Fab fragments: case study. | 2010 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6849743
Methyldigoxin, 11.0 ug/kg was infused over a 5 min period into the right atrium using one of the two
infusion routes available in the side walls of the double-lumen pulmonary artery catheter.
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3569427
After pretreatment of isolated porcine coronary arteries with therapeutic (2.5 X 10(-9) M) was well as with toxic (10(-6) M) doses of beta-methyldigoxin the serotonin-induced contractions were significantly amplified. Since serotonin released from destroyed thrombocytes may be one of the triggering factors eliciting coronary spasms, caution must be taken in the use of digitalis in coronary disease of spastic origin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:25:40 GMT 2025
by
admin
on
Wed Apr 02 08:25:40 GMT 2025
|
Record UNII |
I7GG1YUC5V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC01AA08
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
||
|
WHO-ATC |
C01AA08
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C170170
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
DB13401
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
443946
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
2876
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
6686
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | RxNorm | ||
|
I7GG1YUC5V
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
SUB08887MIG
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
100000091460
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
30685-43-9
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
Metildigoxin
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
D008520
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
250-292-0
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
m4456
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID0023294
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL1697843
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY | |||
|
1761
Created by
admin on Wed Apr 02 08:25:40 GMT 2025 , Edited by admin on Wed Apr 02 08:25:40 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Metabolite to parent drug ratio in non-uraemic human plasma.
The N-desmethyl metabolite has similar efficacy as the parent drug in the treatment of patients with petit mal epilepsy.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |